real-world outcomes of 177lu-psma-617 in mcrpc
Published 5 months ago • 127 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
5:45
efficacy and toxicity of 177lu-psma-617 for mcrpc in a real-world setting
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
10:20
psmafore results: [177lu]lu-psma-617 in taxane-naive patients with mcrpc
-
1:35
vision: safety analysis of 177lu-psma-617 in mcrpc
-
4:48
vision: lu-177-psma-617 in mcrpc
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
1:28
vision: 177lu-psma-617 in psma-positive mcrpc
-
1:06
the benefits of 177lu-psma-617 plus olaparib for prostate cancer
-
1:38
dr. sartor on outcomes with 177lu-psma-617 after radium-223 in mcrpc
-
5:27
177lu-psma-617 radionuclide therapy in mcrpc
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
2:02
the development and results of a dose-intense regimen using 177lu-psma-617 for progressive mcrpc
-
1:00
is there are role for 177lu-psma-617 in earlier lines of treatment for mcrpc?
-
1:09
psma imaging pre- and post-177lu-psma-617 treatment in mcrpc
-
3:25
highlights on lu-psma-617 in taxane-naive patients with mcrpc: the psmafore study
-
1:48
expert discusses fractionated dose 177lu-psma-617 in mcrpc
-
3:17
safety and efficacy of 177lu-psma-617
-
11:39
psmafore trial & enzalutamide with 177lu-psma-617 for mcrpc | dr. dharmender malik | 05th knowledge